Article excerpt:
A study has found that Cannabidiol, the non-psychoactive ingredient in hemp and marijuana, could prove effective in treating opioid addiction. Monica Taing, a board member at Doctors for Cannabis Regulation and one of the nation’s leading experts on the pharmacology and production processes related to cannabis and its components, was hailed Hurd's study, given its implications." This work and future findings may substantiate CBD as a new, viable adjunct therapeutic option to help combat the opioid crisis," she said. "Dr. Hurd’s previous, ongoing, and future studies are meaningful for a new and emerging area of studies to determine facts about this innovative potential pharmacotherapy. "CBD could prove to be an effective and more easily available alternative in the future and help combat the opioid crisis, says Taing, given there are enough side profiles comparing traditional treatment with cannabidiol studies to optimize safety and efficacy for patients. "While more studies evaluating CBD’s therapeutic potential are either being initiated or ongoing, current obstacles include the current state of lacking data to substantiate revising and standardizing national clinical care guidelines, inconsistencies for current federal, state, and local regulations, and lack of fact-based education being offered to healthcare professionals will hinder a prospective CBD treatment for addiction being widely legalized," Taing said, adding that fact-based education for the general public, the healthcare community, and integral decision-makers could help facilitate the process of legalizing it as a potential treatment.
Read the full article at Media Entertainment Arts WorldWide
Monica Taing, PharmD, RPh graduated from Northeastern University in Boston, Massachusetts with a Doctor of Pharmacy degree and a Bachelor of Science degree in Pharmacy Studies where she completed Endocannabinoid Receptor System research. Since becoming the first Patient Experience Manager at a licensed alternative treatment center in New Jersey, today Dr. Taing is a clinical cannabis consultant for licensed dispensaries, hospital systems, and academic medical institutions in multiple states. Dr. Taing is the first Medical Science Liaison for 4Front Ventures, the National Director of Research & Clinical Education for Minorities for Medical Marijuana (M4MM), a clinical consultant specialist for Columbia University’s Northeast/Caribbean AIDS Education Training Center (NEC-AETC), and sits on the Editorial Board of the American Journal of Endocannabinoid Medicine (AJEM). Dr. Taing is passionate about clinical research, patient counseling, public health education, multidisciplinary clinical outreach, and harm reduction advocacy for under-served patient populations.
.svg)